# Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

> **NCT01492088** · PHASE1,PHASE2 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Relapsed or Refractory Hodgkin Lymphoma
- Relapsed or Refractory Anaplastic Large-cell Lymphoma

## Interventions

- **DRUG:** Brentuximab vedotin

## Key facts

- **NCT ID:** NCT01492088
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-16
- **Primary completion:** 2016-10-12
- **Final completion:** 2018-04-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2024-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01492088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01492088, "Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01492088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*